A Phase 2 interventional study of LCZ696 and Valsartan in Systolic Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 90 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-29.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Isolated Systolic Hypertension with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Isolated Systolic Hypertension · United States.
Among the 13 studies in Isolated Systolic Hypertension with a site in United States, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2011, is one of 3 in phase 2, and was the 7th registered.
35 studies on the registry are indexed under Isolated Systolic Hypertension; 8 are open to participants now.
Browse Isolated Systolic Hypertension studies →3 of the 13 studies in Isolated Systolic Hypertension with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 18+
Orchestra BioMed, Inc · Sites in United States, Australia, Belgium and 12 more countries
Ages 18+
Marshall University · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Isolated Systolic Hypertension studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 910 is above the median of 100 across 31 interventional studies indexed under Isolated Systolic Hypertension.
Median enrollment 145 across the 12 interventional studies, 60 across the 1 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 13 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 3 studies filed under Isolated Systolic Hypertension — fewer than ten, so there is no comparison to draw.
2 of the studies in Isolated Systolic Hypertension with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2026-12 |
| NCT07109739University of MinnesotaDose-Response Effects of Inspiratory Muscle Strength Training on Blood Pressure and Vascular Function | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Isolated Systolic Hypertension with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were started with AHU377 100 mg + valsartan 160 mg every day (qd) for 1 week, then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for another week, and then were uptitrated to AHU377 400 mg + valsartan 320 mg for the remaining 6 weeks.
Drug: Valsartan · Drug: AHU377
Participants were started with AHU377 100 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for the remaining 7 weeks.
Drug: Valsartan · Drug: AHU377
Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 100 mg + valsartan 320 mg for the remaining 7 weeks.
Drug: Valsartan · Drug: AHU377
Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 50 mg + valartan 320 mg qd for the remaining 7 weeks.
Drug: Valsartan · Drug: AHU377
Participants were started with valsartan 160 mg qd for 1 week and then were uptitrated to valsartan 320 mg qd for the remaining 7 weeks.
Drug: Valsartan
Participants were started with LCZ696 200 mg qd for 1 week and then were uptitrated to LCZ696 400 mg qd for the remaining 7 weeks.
Drug: LCZ696
Participants received matching placebo to LCZ696, AHU377 and valsartan for 8 weeks.
Drug: Placebo
LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
Placebo was supplied as tablets in blister cards.
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
Time frame: Baseline, 8 weeks
Change From Baseline in Mean Diastolic Blood Pressure (msDBP)
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
Time frame: Baseline, 8 weeks
Change From Baseline in Mean 24 Hour Ambulatory SBP (maSBP) and Mean 24 Hour Ambulatory DBP (maDBP)
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Time frame: Baseline, 8 weeks
Change From Baseline in Daytime maSBP and maDBP
Twenty four hour ABPM was performed twice during the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Time frame: Baseline, 8 weeks
Change From Baseline in Nighttime maSBP and maDBP
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Time frame: Baseline and 8 weeks
Change From Baseline in Mean Sitting Pulse Pressure
Pulse rate measurements were performed. A negative change from baseline indicates improvement.
Time frame: Baseline, 8 weeks
Change From Baseline in Mean Ambulatory Pulse Pressure
Pulse rate measurements were performed. A negative change from baseline indicates improvement.
Time frame: Baseline, 8 weeks
Change From Baseline in maSBP and maDBP in Dippers
Twenty four hour ABPM was performed twice during the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement.
Time frame: Baseline, 8 weeks
Change From Baseline in maSBP and maDBP in Non-dippers
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement.
Time frame: Baseline, 8 weeks
Change From Baseline in msSBP and msDBP in Participants < 65 Years of Age
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
Time frame: Baseline, 8 weeks
Change From Baseline in msSBP and msDBP in Participants >= 65 Years of Age
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
Time frame: Baseline, 8 weeks
Change From Baseline in maSBP and maDBP in Participants < 65 Years of Age
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Time frame: Baseline, 8 weeks
Change From Baseline in maSBP and maDBP in Participants >= 65 Years of Age
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
Time frame: Baseline, 8 weeks
Number of Participants Who Achieved Blood Pressure Control and Blood Pressure Response
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). Blood pressure control was defined as msSBP/MSDBP \< 140/90 mmHg. Blood pressure response in msSBP was defined as \<140 mmHg or a reduction \>= 20mmHg from baseline. Blood pressure response in msDBP was defined as \< 90 mmHg or a reduction \>= 10 mmHg from baseline.
Time frame: 8 weeks
Number of Participants With Adverse Events, Serious Adverse Events and Death
Adverse event monitoring was conducted throughout the study.
Time frame: 8 weeks
This study consisted of a single-blind run-in period and a double-blind (DB) period. During the 3 to 4 week run-in, participants were assessed for randomization eligibility into the DB period. 910 participants randomized. 3 participants were mis-randomized and did not receive study treatment. Therefore, the participant flow shows 907 participants.
| Milestone | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Started | 144 | 145 | 141 | 134 | 143 | 142 | 58 |
| Full analysis set | 143 | 145 | 141 | 133 | 143 | 142 | 58 |
| Safety set | 143 | 145 | 141 | 133 | 143 | 142 | 58 |
| Ambulatory blood pressure monitoring set | 95 | 99 | 92 | 95 | 93 | 91 | 35 |
| Completed | 136 | 141 | 133 | 123 | 134 | 135 | 51 |
| Not completed | 8 | 4 | 8 | 11 | 9 | 7 | 7 |
| Withdrew: Lack of efficacy | 0 | 1 | 3 | 0 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 2 | 4 | 1 | 3 | 1 |
| Withdrew: Protocol deviation | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Condition no longer requires study drug | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 2 | 2 | 3 | 5 | 3 | 3 |
| Withdrew: Randomized in error | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) | -20.89 ± 1.22 | -23.55 ± 1.21 | -21.26 ± 1.23 | -19.31 ± 1.27 | -16.13 ± 1.22 | -21.78 ± 1.22 | -6.99 ± 1.92 |
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Mean Diastolic Blood Pressure (msDBP) | -8.47 ± 0.76 | -9.76 ± 0.75 | -8.04 ± 0.76 | -7.15 ± 0.79 | -7.28 ± 0.76 | -9.61 ± 0.75 | -3.38 ± 1.19 |
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| maSBP | -12.14 ± 0.71 | -15.66 ± 0.69 | -14.33 ± 0.72 | -11.36 ± 0.70 | -9.59 ± 0.71 | -12.98 ± 0.71 | -2.12 ± 1.15 |
| maDBP | -5.81 ± 0.44 | -7.03 ± 0.42 | -6.46 ± 0.44 | -5.36 ± 0.43 | -5.23 ± 0.44 | -6.20 ± 0.44 | -0.79 ± 0.71 |
Twenty four hour ABPM was performed twice during the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| maSBP | -12.62 ± 1.21 | -15.85 ± 1.19 | -14.43 ± 1.23 | -11.50 ± 1.21 | -9.60 ± 1.22 | -13.32 ± 1.23 | -2.39 ± 1.98 |
| maDBP | -5.93 ± 0.77 | -7.13 ± 0.75 | -6.57 ± 0.78 | -5.39 ± 0.77 | -5.40 ± 0.77 | -6.16 ± 0.78 | -0.98 ± 1.26 |
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| maSBP | -11.57 ± 1.23 | -15.27 ± 1.19 | -14.74 ± 1.23 | -10.80 ± 1.21 | -8.88 ± 1.22 | -12.34 ± 1.23 | -1.36 ± 1.98 |
| maDBP | -5.27 ± 0.78 | -6.79 ± 0.75 | -6.45 ± 0.78 | -5.27 ± 0.77 | -4.49 ± 0.77 | -6.36 ± 0.78 | -0.22 ± 1.26 |
Pulse rate measurements were performed. A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Mean Sitting Pulse Pressure | -12.39 ± 0.91 | -13.91 ± 0.90 | -13.18 ± 0.91 | -12.01 ± 0.95 | -8.80 ± 0.91 | -12.18 ± 0.91 | -3.74 ± 1.43 |
Pulse rate measurements were performed. A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Mean Ambulatory Pulse Pressure | -6.23 ± 0.39 | -8.51 ± 0.38 | -7.71 ± 0.40 | -6.00 ± 0.39 | -4.40 ± 0.39 | -6.84 ± 0.39 | -1.09 ± 0.63 |
Twenty four hour ABPM was performed twice during the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| maSBP | -11.43 ± 1.12 | -15.59 ± 1.00 | -12.04 ± 1.05 | 10.60 ± 1.01 | -9.85 ± 1.03 | -13.09 ± 1.05 | -2.39 ± 1.45 |
| maDBP | -4.62 ± 0.70 | -7.33 ± 0.62 | -5.49 ± 0.65 | -5.07 ± 0.63 | -5.53 ± 0.64 | -6.03 ± 0.65 | -0.98 ± 0.90 |
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. Dippers were defined as participants who showed a decrease of at least 10% in maSBP during the night (10pm-6am) compared with the daytime level. A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| maSBP | -12.81 ± 0.91 | -16.08 ± 0.94 | -16.37 ± 0.97 | -12.17 ± 0.99 | -9.73 ± 0.96 | -13.12 ± 0.96 | -1.46 ± 1.75 |
| maDBP | -6.65 ± 0.56 | -6.91 ± 0.58 | -7.31 ± 0.60 | -5.79 ± 0.61 | -5.10 ± 0.59 | -6.34 ± 0.59 | -0.49 ± 1.08 |
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| msSBP | -20.95 ± 1.68 | -24.45 ± 1.67 | -20.94 ± 1.63 | -18.09 ± 1.79 | -16.96 ± 1.71 | -21.06 ± 1.63 | -8.94 ± 2.73 |
| msDBP | -8.97 ± 1.11 | -10.94 ± 1.11 | -8.83 ± 1.09 | -8.07 ± 1.19 | -6.93 ± 1.13 | -10.25 ± 1.08 | -5.19 ± 1.82 |
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| msSBP | -20.93 ± 1.79 | -22.66 ± 1.76 | -21.72 ± 1.85 | -20.64 ± 1.81 | -15.48 ± 1.75 | -22.83 ± 1.84 | -5.10 ± 2.71 |
| msDBP | -7.89 ± 1.02 | -8.44 ± 1.00 | -7.06 ± 1.05 | -6.17 ± 1.03 | -7.62 ± 0.99 | -8.89 ± 1.04 | -1.46 ± 1.54 |
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| maSBP | -12.16 ± 0.98 | -15.06 ± 0.91 | -14.42 ± 0.95 | -10.39 ± 0.95 | -9.55 ± 0.99 | -13.98 ± 0.93 | -2.24 ± 1.67 |
| maDBP | -6.74 ± 0.67 | -7.81 ± 0.62 | -7.93 ± 0.65 | -5.69 ± 0.65 | -5.94 ± 0.67 | -7.32 ± 0.63 | -1.53 ± 1.14 |
Twenty four hour ABPM was performed twice duirng the study at baseline and week 8. The second ABPM assessment was performed only in participants who had successfully completed the ABPM assessment at baseline. A negative change from baseline indicates improvement.
| mmHg | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| maSBP | -12.10 ± 1.04 | -16.08 ± 1.03 | -14.20 ± 1.08 | -12.25 ± 1.04 | -9.73 ± 1.02 | -11.88 ± 1.10 | -1.95 ± 1.59 |
| maDBP | -4.94 ± 0.58 | -6.00 ± 0.57 | -4.86 ± 0.60 | -4.93 ± 0.58 | -4.58 ± 0.56 | -5.04 ± 0.61 | -0.01 ± 0.88 |
Sitting BP measurements were performed at trough (23-26 hours post-morning dose). Blood pressure control was defined as msSBP/MSDBP \< 140/90 mmHg. Blood pressure response in msSBP was defined as \<140 mmHg or a reduction \>= 20mmHg from baseline. Blood pressure response in msDBP was defined as \< 90 mmHg or a reduction \>= 10 mmHg from baseline.
| Number of participants | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Blood pressure control | 72 | 86 | 71 | 58 | 57 | 76 | 8 |
| msSBP response | 88 | 101 | 93 | 81 | 72 | 94 | 11 |
| msDBP response | 112 | 126 | 114 | 101 | 111 | 118 | 39 |
Adverse event monitoring was conducted throughout the study.
| Number of participants | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Adverse events (non-serious and serious) | 40 | 31 | 29 | 25 | 38 | 42 | 20 |
| Serious adverse events | 3 | 1 | 1 | 0 | 1 | 1 | 1 |
| Deaths | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VAL + AHU 400 mg | — | 3/143 (2.1%) | 1/143 (0.7%) |
| VAL + AHU 200 mg | — | 1/145 (0.7%) | 2/145 (1.4%) |
| VAL + AHU 100 mg | — | 1/141 (0.7%) | 1/141 (0.7%) |
| VAL + AHU 50 mg | — | 0/133 (0%) | 2/133 (1.5%) |
| VAL 320 mg | — | 1/143 (0.7%) | 4/143 (2.8%) |
| LCZ 400 mg | — | 1/142 (0.7%) | 1/142 (0.7%) |
| Placebo | — | 1/58 (1.7%) | 3/58 (5.2%) |
| Event | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Calculus urinaryRenal and urinary disorders | 0/143 | 0/145 | 0/141 | 0/133 | 0/143 | 0/142 | 1/58 |
| Postoperative wound infectionInfections and infestations | 0/143 | 0/145 | 1/141 | 0/133 | 0/143 | 0/142 | 0/58 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/143 | 0/145 | 0/141 | 0/133 | 0/143 | 1/142 | 0/58 |
| Sudden deathGeneral disorders | 1/143 | 0/145 | 0/141 | 0/133 | 0/143 | 0/142 | 0/58 |
| CholelithiasisHepatobiliary disorders | 1/143 | 0/145 | 0/141 | 0/133 | 0/143 | 0/142 | 0/58 |
| Thoracic vertebral fractureInjury, poisoning and procedural complications | 0/143 | 0/145 | 0/141 | 0/133 | 1/143 | 0/142 | 0/58 |
| AngioedemaSkin and subcutaneous tissue disorders | 1/143 | 0/145 | 0/141 | 0/133 | 0/143 | 0/142 | 0/58 |
| SchizophreniaPsychiatric disorders | 0/143 | 1/145 | 0/141 | 0/133 | 0/143 | 0/142 | 0/58 |
| Event | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo |
|---|---|---|---|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 1/143 | 2/145 | 1/141 | 2/133 | 4/143 | 1/142 | 3/58 |
| Age, Continuous(Years) | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 61.7 ± 11.36 | 61.7 ± 11.44 | 61.0 ± 11.03 | 62.0 ± 10.73 | 62.0 ± 11.45 | 61.2 ± 10.60 | 60.8 ± 11.81 | 61.5 ± 11.13 |
| Sex: Female, Male(Participants) | VAL + AHU 400 mg | VAL + AHU 200 mg | VAL + AHU 100 mg | VAL + AHU 50 mg | VAL 320 mg | LCZ 400 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 78 | 60 | 53 | 61 | 60 | 71 | 29 | 412 |
| Male | 66 | 85 | 88 | 73 | 83 | 71 | 29 | 495 |
The record gives a start of Jan 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 3 years 8 months after primary completion. A results delay was requested in Jan 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Sacubitril
Isolated Systolic Hypertension →